Figure 2.
Clinical course of the patient from the admission day to the discharge day (day 113). Lymphocyte follows left axis and LDH follows right axis. After debulking by CPA+PSL+Rituximab, venetoclax was started, and the dose was increased gradually; the treatment response was good. Because of the complications of CRBSI, venetoclax treatment was stopped. After the exchange of the catheter and antibiotic therapy, venetoclax was restarted safely.
*Ven: venetoclax, CPA: cyclophosphamide, CRBSI: catheter-related bloodstream infection, PSL: prednisolone, R: rituximab.